Evaluation of antiinflammatory and antioxidant effect of mepenzolate in subacute cigarette exposure mouse model

Aim: Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease mainly caused by tobacco smoke inhalation. We aimed to evaluate antiinflamatory and antioxidant effect of mepenzolate bromide which is a muscarinic antagonist in subacute cigarette exposure mice model. Method: Forty seven healthy 25-40 gram male mices were categorized into 4 groups: (A) control group (n=7), (B) exposed to cigarette smoke (CS) (n=18), and (C) exposed to CS treated with 400 mikrogram/kg/ day mepenzolate group(n=14),( D) treated with 400 mikrogram/kg/ day mepenzolate group (n=8). After 5 weeks, mepenzolate or saline was given to mices during two weeks by inhalation. Mices were anesthetized, broncoalveolar lavage (BAL) was performed, lung tissues was removed. Interleukin-1β (IL1β), macrophage inflammatory protein-1 (MIP 1), tumor necrosis factor alpha (TNF α) measurements were evaluated in BAL fluid and total oxidant and antioxsidant status (TAS-TOS) were measured in lung tissues. Results: We found that cigarettes exposure significantly decreased TAS and increased TOS (p Conclusions: Mepenzolate may be a promising therapeutic choice to reduce oxidative effect and to control inflammation due to cigarette exposure.